biostudies-literatureHennessee INational Institute of Neurological Disorders and StrokeNINDS NIH HHSNational Institutes of HealthNIH HHS364-366https://www.ebi.ac.uk/biostudies/studies/S-EPMC11848264biostudies-literatureUnknown80(2)In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaIncidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor-Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis.PMC11848264K23 NS110470Bahr NCGold JAWLipner SRHennessee IBenedict KfalseIncidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor-Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis.In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.2025-01-01T00:00:00Z2025 Feb2025-04-04T09:10:00.091Z2025-04-04T09:10:00.091ZS-EPMC118482643922372010.1093/cid/ciae444